Investigating how targeting Nell2 and GABA dysfunction can help Alzheimer's patients with the APOE4 gene.
Targeting Nell2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease
This study is looking at how a gene called APOE4, which is linked to Alzheimer's disease, affects brain function in older adults, and it hopes to find new ways to help improve thinking skills for those living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11100623 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the APOE4 gene, a major risk factor for Alzheimer's disease, and how it affects brain function, particularly in older adults. The study aims to explore the relationship between APOE4, GABAergic dysfunction, and cognitive decline, using both animal models and clinical observations. By examining how these factors interact, the research seeks to identify potential therapeutic strategies that could mitigate cognitive impairment in individuals with Alzheimer's disease. Patients may benefit from insights gained about the mechanisms of their condition and potential new treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are carriers of the APOE4 gene and may be experiencing cognitive decline.
Not a fit: Patients who are younger than 65 or do not carry the APOE4 gene may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cognitive function and quality of life for Alzheimer's patients carrying the APOE4 gene.
How similar studies have performed: Previous studies have shown promising results in targeting similar pathways in Alzheimer's disease, indicating potential for success in this novel approach.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Zilberter, Misha Yuri — J. David Gladstone Institutes
- Study coordinator: Zilberter, Misha Yuri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.